Puma Biotechnology(US:PBYI)2023-03-08 17:42Commercial Performance - Puma Biotechnology achieved approximately $54 million in net NERLYNX revenue in Q4 2022[21] - 3,323 ex-factory bottles of NERLYNX were sold in Q4 2022[16], including sales from the Commercial Specialty Pharmacy Network (SP) and Specialty Distributor Network (SD)[17] - The company's quarterly net revenue has fluctuated, with figures ranging from $2.68 million to $5.538 million across different periods[10] Dosage and Treatment - Approximately 64% of patients in Q4 2022 initiated treatment with a reduced dose of NERLYNX[4] Global Expansion - NERLYNX has received regulatory approvals in several regions, including Australia/SE Asia, Israel, Canada, Latin America, Europe, Greater China, Middle East, North and West Africa, South Africa, Turkey, and South Korea[19] - Commercial launches of NERLYNX have occurred in various countries, including Singapore, Malaysia, Brunei, New Zealand, Argentina, Chile, Peru, Brazil, Mexico, Germany, UK, Austria, Sweden, Finland, Scotland, Switzerland, Denmark, Hong Kong, China, Taiwan, Greece, Czech Republic, Ireland, Spain and South Korea[19] Distribution Network - Puma Biotechnology utilizes a pharmacy and distributor network that includes Specialty Pharmacies (SP) such as Acaria Health, Accredo, CVS ONCO 360, and Optum/Diplomat Biologics, and Specialty Distributors (SD) such as Cardinal Health, McKesson, ASD/Oncology Supply, and DMS Pharmaceutical Group Inc[1,8]